Table 1.
Baseline characteristics of patients enrolled in this study
| Characteristic | Healthy control group (n = 18) | SHF stage F2 groupa (n = 18) | t-test (n = 18)b | P* | SHF stage F4 groupa (n = 18) | t-test (n = 18)c | P§ |
|---|---|---|---|---|---|---|---|
| Gender (female/male) | 9/9 | 8/10 | N/A | N/A | 10/8 | N/A | N/A |
| Age (years) | 74.83 ± 6.11 | 74.94 ± 6.73 | − 0.052 | 0.959 | 75.00 ± 5.48 | − 0.270 | 0.978 |
| ALT (U/l) | 13.72 ± 3.34 | 17.17 ± 5.32 | − 2.328 | 0.026 | 35.89 ± 4.59§ | − 11.312 | < 0.001 |
| AST (U/L) | 18.44 ± 4.02 | 32.50 ± 7.34* | − 7.125 | < 0.001 | 47.78 ± 9.52§ | − 5.391 | < 0.001 |
| ALP (U/l) | 29.11 ± 7.11 | 85.44 ± 15.89* | − 13.725 | < 0.001 | 150.40 ± 42.11§ | − 6.112 | < 0.001 |
| GGT (U/l) | 21.39 ± 7.51 | 32.56 ± 19.25 | − 2.292 | 0.032 | 146.39 ± 125.98§ | − 3.789 | 0.001 |
| PLT (109 l−1) | 220.61 ± 41.52 | 92.33 ± 17.99* | 12.027 | < 0.001 | 42.83 ± 19.78§ | 7.855 | < 0.001 |
| TB (umol/l) | 6.34 ± 1.49 | 15.67 ± 4.03* | − 9.203 | < 0.001 | 29.59 ± 14.95§ | − 3.816 | 0.001 |
| TBA (umol/l) | 2.78 ± 1.40 | 3.88 ± 2.28 | − 1.734 | 0.092 | 25.69 ± 14.50§ | − 6.304 | < 0.001 |
| Albumin (g/l) | 48.32 ± 3.23 | 47.59 ± 2.53 | 0.747 | 0.461 | 39.46 ± 2.83§ | 9.101 | < 0.001 |
| APRI | 0.67 ± 0.18 | 2.73 ± 0.48* | − 16.921 | < 0.001 | 10.15 ± 4.76§ | − 6.584 | < 0.001 |
| PT (s) | N/A | 12.89 ± 0.62 | N/A | N/A | 15.52 ± 1.27§ | − 7.906 | < 0.001 |
| INR | N/A | 1.00 ± 0.05 | N/A | N/A | 1.20 ± 0.10§ | − 7.821 | < 0.001 |
| APTT (s) | N/A | 37.27 ± 3.23 | N/A | N/A | 42.31 ± 3.09§ | − 4.786 | < 0.001 |
| FIB (g/l) | N/A | 2.95 ± 0.58 | N/A | N/A | 2.32 ± 0.43§ | 3.696 | 0.001 |
Values in table are present as the mean ± standard deviation
ALP Alkaline phosphatase, ALT alanine aminotransferase, APRI AST-to-PLT ratio index, APTT activated partial thromboplastin, AST aspartate aminotransferase, FIB fibrinogen content, GGT gamma-glutamyltranspeptidase, INR international normalized ratio, N/A information not available, PLT platelet count, SHF schistosomiasis-induced hepatic fibrosis, PT prothrombin time, TB total bilirubin, TBA total bile acid
*P value < 0.05 for comparisons between patients with SHF stage F2 and healthy controls, and §P value < 0.05 for comparisons between patients with SHF stage F4 and and those with SHF stage F2.
aSHF was staged from F0 to F4 according the METAVIR scoring system
bStudent’s t-test for comparisons between patients with SHF stage F2 and healthy controls
cStudent’s t-test for comparisons between patients with SHF stage F4 and those with SHF stage F2